GO:0051996 squalene synthase [NAD(P)H] activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051996 (squalene synthase [NAD(P)H] activity) catalyzes the reductive dimerization of two molecules of (2E,6E)-farnesyl diphosphate to form squalene, consuming NAD(P)H and releasing two diphosphate groups.
• The enzyme is a membrane-associated protein anchored to the endoplasmic reticulum, with its catalytic domain facing the cytosol.
• Squalene synthase is a key branch-point enzyme in the mevalonate pathway, committing carbon flux to sterol and triterpenoid biosynthesis.
• Its activity is regulated at transcriptional, post-transcriptional, and post-translational levels, including feedback by sterols and downregulation by inflammatory cytokines.
• The enzyme contains three catalytic domains that cooperate in the two-step conversion of farnesyl diphosphate to squalene via a presqualene diphosphate intermediate.
• Squalene synthase is a target for antifungal, hypocholesterolemic, and anti-trypanosomal drug development, and its homologs occur in diverse organisms including microalgae.
Description
Squalene synthase [NAD(P)H] activity (GO:0051996) is a molecular function that catalyzes the committed step in sterol biosynthesis: the reductive condensation of two farnesyl diphosphate molecules to form squalene. This reaction sits at the first branch point of the mevalonate pathway, directing carbon flux toward sterols, triterpenoids, and related isoprenoids. Because of its central role in cholesterol and ergosterol production, the enzyme has been extensively studied as a drug target and as a model for membrane-bound prenyltransferases. Researchers investigating lipid metabolism, membrane biogenesis, and isoprenoid diversity rely on precise characterization of this activity to understand how cells allocate resources between sterol and non-sterol end products.
squalene synthase [NAD(P)H] activity At A Glance
| GO ID | GO:0051996 |
|---|---|
| GO term | squalene synthase [NAD(P)H] activity |
| Ontology | molecular_function |
| Synonym | farnesyl-diphosphate farnesyltransferase activity; farnesyltransferase activity; presqualene-diphosphate synthase activity; presqualene synthase activity; squalene synthase activity; squalene synthetase activity |
| Major function | Reductive dimerization of two farnesyl diphosphate molecules to form squalene, the first committed step in sterol biosynthesis. |
| Reaction | 2 (2E,6E)-farnesyl diphosphate + H+ + NAD(P)H = 2 diphosphate + NAD(P)+ + squalene. |
| Cofactor | NAD(P)H as electron donor; divalent metal ions (e.g., Mg2+ or Mn2+) required for catalysis. |
| Subcellular localization | Endoplasmic reticulum membrane; catalytic domain faces the cytosol. |
| Pathway | Mevalonate pathway / sterol biosynthesis. |
What Is GO:0051996?
According to the Gene Ontology, GO:0051996 (squalene synthase [NAD(P)H] activity) is defined as the catalysis of the reaction: 2 (2E,6E)-farnesyl diphosphate + H+ + NAD(P)H = 2 diphosphate + NAD(P)+ + squalene. In other words, it is the NAD(P)H-dependent reductive dimerization of two farnesyl diphosphate molecules to produce squalene, a linear triterpene precursor of all sterols. The reaction proceeds through a presqualene diphosphate intermediate and requires a divalent metal ion for catalysis.
Why Is squalene synthase [NAD(P)H] activity Important in Cell Biology?
Squalene synthase [NAD(P)H] activity is critically important because it represents the first committed and rate-controlling step in the biosynthesis of sterols, which are essential for membrane integrity, hormone production, and lipoprotein assembly. The enzyme also serves as a regulatory hub that integrates signals from sterol levels, inflammatory cytokines, and developmental cues to modulate carbon flux through the mevalonate pathway. Its unique two-step catalytic mechanism, involving a cyclopropylcarbinyl intermediate, has made it a paradigm for studying prenyltransferase chemistry and a target for therapeutic intervention in hypercholesterolemia, fungal infections, and parasitic diseases.
• Controls the committed step of sterol biosynthesis, influencing cholesterol and ergosterol production.
• Regulates carbon flux at the branch point between sterol and non-sterol isoprenoid pathways.
• Is a validated target for hypocholesterolemic drugs and antifungal agents.
• Its activity is downregulated by inflammatory cytokines such as TNF and IL-1, linking lipid metabolism to inflammation.
• Plays a role in the biosynthesis of triterpenoids and related natural products in plants and microalgae.
• Its membrane-bound nature and catalytic mechanism provide a model for studying ER-associated enzymes.
• Alterations in squalene synthase activity have been implicated in metabolic disorders and cancer cell proliferation.
• The enzyme is essential in pathogenic protozoa, making it a potential drug target for neglected tropical diseases.
What Happens During squalene synthase [NAD(P)H] activity?
Substrate binding and first half-reaction
In simple terms: Two identical molecules of farnesyl diphosphate come together, and the enzyme helps them join in a head-to-head fashion.
The reaction begins with the binding of two molecules of (2E,6E)-farnesyl diphosphate to the active site of squalene synthase. The enzyme catalyzes the condensation of these two molecules to form a cyclopropylcarbinyl intermediate, presqualene diphosphate, with the release of one diphosphate group. This step is thought to proceed via an ionization-condensation-elimination mechanism involving a carbocation intermediate stabilized by the enzyme.
Second half-reaction and squalene formation
In simple terms: The intermediate is rearranged and reduced, using NAD(P)H, to produce squalene.
In the second step, presqualene diphosphate undergoes a reductive rearrangement that involves NAD(P)H as the electron donor, leading to the formation of squalene and the release of a second diphosphate group. This step is unique among prenyltransferases because it couples a rearrangement with a reduction, and it requires the cofactor NAD(P)H (or NADH). The overall reaction is irreversible under physiological conditions, committing the carbon flux to sterol biosynthesis.
Role of catalytic domains
In simple terms: The enzyme has several distinct parts that work together to perform the two-step reaction.
Structure-function studies of rat hepatic squalene synthase have identified three enzyme domains involved in catalytic activity. These domains cooperate to bind the two farnesyl diphosphate substrates, stabilize the presqualene diphosphate intermediate, and facilitate the NAD(P)H-dependent reduction. Mutagenesis of conserved residues within these domains abolishes or severely reduces catalytic activity, confirming their essential roles.
Membrane association and localization
In simple terms: The enzyme is anchored to the membrane of the endoplasmic reticulum, with its active part facing the cytosol.
Squalene synthase is a membrane-bound enzyme localized to the endoplasmic reticulum (ER) in mammalian cells. Biochemical and immunochemical evidence indicates that the protein is anchored to the ER membrane via a hydrophobic C-terminal domain, while the catalytic domain faces the cytosol. This topology allows the enzyme to access cytosolic farnesyl diphosphate and NAD(P)H while remaining associated with the ER, where downstream sterol biosynthetic enzymes reside.
Key Genes Involved in GO:0051996 squalene synthase [NAD(P)H] activity
The following genes and proteins are directly involved in or closely associated with squalene synthase [NAD(P)H] activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FDFT1 (SQS) | Encodes squalene synthase, the enzyme catalyzing GO:0051996 | Primary target for studying sterol biosynthesis and drug development |
| HMGCR | Rate-limiting enzyme of mevalonate pathway upstream of squalene synthase | Provides substrate flux and is coordinately regulated with FDFT1 |
| FDPS | Farnesyl diphosphate synthase, produces the substrate farnesyl diphosphate | Supplies substrate for squalene synthase; peroxisomal localization studied |
| SQLE | Squalene epoxidase, converts squalene to 2,3-oxidosqualene | Downstream enzyme; its inhibition leads to squalene accumulation |
| LSS | Lanosterol synthase, cyclizes 2,3-oxidosqualene to lanosterol | Downstream of squalene synthase in sterol pathway |
| SREBF2 | Sterol regulatory element-binding protein 2, transcription factor | Regulates expression of FDFT1 and other sterol genes |
| INSIG1 | Insulin-induced gene 1, regulates SREBP processing | Modulates sterol synthesis including squalene synthase levels |
| NFKB1 | Nuclear factor kappa B subunit 1, mediates inflammatory signaling | Inflammatory cytokines downregulate squalene synthase via NF-kB |
| TNF | Tumor necrosis factor, pro-inflammatory cytokine | Decreases hepatic squalene synthase activity and mRNA |
| IL1B | Interleukin 1 beta, pro-inflammatory cytokine | Reduces squalene synthase expression in liver |
| CYP51A1 | Lanosterol 14-alpha demethylase, sterol biosynthesis | Coordinate regulation with squalene synthase |
| DHCR7 | 7-dehydrocholesterol reductase, cholesterol synthesis | Downstream of squalene synthase; mutations cause Smith-Lemli-Opitz syndrome |
| MVK | Mevalonate kinase, early mevalonate pathway | Upstream of squalene synthase; mutations cause mevalonate kinase deficiency |
| PMVK | Phosphomevalonate kinase | Upstream enzyme in mevalonate pathway |
| MVD | Mevalonate decarboxylase | Upstream enzyme providing isopentenyl diphosphate |
| IDI1 | Isopentenyl-diphosphate delta isomerase 1 | Upstream of farnesyl diphosphate synthesis |
| GGPS1 | Geranylgeranyl diphosphate synthase | Competes for farnesyl diphosphate with squalene synthase |
| BOTRYOCOCCENE_SYNTHASE | Squalene synthase-like enzyme in Botryococcus braunii | Produces botryococcene, a triterpene hydrocarbon |
How Is squalene synthase [NAD(P)H] activity Regulated?
Squalene synthase [NAD(P)H] activity is regulated at multiple levels. Transcriptionally, the FDFT1 gene is controlled by sterol regulatory element-binding proteins (SREBPs), which sense cellular sterol levels and activate expression when sterols are depleted. Post-transcriptionally, the enzyme is subject to feedback regulation by sterols and non-sterol isoprenoids, which can accelerate its degradation. Inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1) decrease hepatic squalene synthase activity, protein, and mRNA levels in vivo, linking inflammation to reduced sterol synthesis. Additionally, the enzyme requires NAD(P)H and divalent metal ions for activity, and its membrane environment may influence catalytic efficiency.
squalene synthase [NAD(P)H] activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FDFT1 | Hypercholesterolemia, cardiovascular disease | Hepatocyte-specific knockout or knock-in of point mutations |
| FDFT1 | Cancer cell proliferation | Cancer cell lines with FDFT1 overexpression or knockout |
| FDFT1 | Antifungal drug target | Fungal strains with conditional FDFT1 knockdown |
| FDFT1 | Trypanosomiasis, leishmaniasis | Parasite lines with CRISPR knockout of squalene synthase |
| TNF/IL1B | Inflammation-induced hypocholesterolemia | Cytokine-treated hepatocytes or in vivo models |
Squalene synthase in hypercholesterolemia and cardiovascular disease
Squalene synthase is a key enzyme in cholesterol biosynthesis, and its inhibition reduces plasma cholesterol levels in animal models. Because it catalyzes the first committed step in sterol synthesis, pharmacological inhibition of squalene synthase has been explored as a strategy for treating hypercholesterolemia and atherosclerosis. However, compensatory upregulation of HMG-CoA reductase and other pathway enzymes can limit efficacy, highlighting the need for combination therapies.
Role in cancer metabolism
Altered cholesterol metabolism is a hallmark of cancer, and squalene synthase expression is often elevated in tumor cells to support rapid proliferation. Inhibition of squalene synthase can reduce cancer cell growth in vitro and in vivo, suggesting its potential as a therapeutic target. The enzyme also contributes to the synthesis of isoprenoids that are required for cell signaling and membrane integrity in cancer cells.
Infectious disease and antifungal targeting
Squalene synthase is essential in fungi and protozoan parasites, where it produces sterols required for membrane function. The enzyme is a validated target for antifungal drugs, and its unique two-step mechanism has inspired the development of specific inhibitors. In Trypanosoma and Leishmania, squalene synthase inhibitors show antiparasitic activity, offering a potential route for neglected tropical disease therapy.
Inflammation and metabolic disorders
Inflammatory cytokines such as TNF and IL-1 decrease hepatic squalene synthase activity, protein, and mRNA levels, suggesting a link between inflammation and dysregulated lipid metabolism. This downregulation may contribute to the hypocholesterolemia observed in chronic inflammatory states and may affect the availability of isoprenoids for protein prenylation.
From squalene synthase [NAD(P)H] activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of complete loss of squalene synthase on cholesterol synthesis? | FDFT1 knockout cell lines (e.g., HepG2, HEK293) |
| How do point mutations in catalytic domains affect enzyme activity? | Knock-in of point mutations in FDFT1 (e.g., D219A, R218A) |
| How does squalene synthase localization affect its function? | Knock-in of tagged FDFT1 (e.g., GFP or HA) for imaging |
| What is the effect of squalene synthase overexpression on lipid accumulation? | Overexpression of FDFT1 in hepatocytes or adipocytes |
| How does inflammatory signaling regulate squalene synthase? | Cytokine-treated cells with FDFT1 promoter reporters |
| Can squalene synthase inhibitors reduce tumor growth? | Xenograft models with FDFT1-overexpressing cancer cells |
How to Study the squalene synthase [NAD(P)H] activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiometric enzyme assay | Conversion of [3H]farnesyl diphosphate to squalene | Kinetic characterization and inhibitor screening |
| Spectrophotometric assay | NAD(P)H oxidation at 340 nm | High-throughput screening of squalene synthase inhibitors |
| qRT-PCR | FDFT1 mRNA levels | Regulation by sterols and cytokines |
| Western blot | Squalene synthase protein levels | Protein stability and post-translational regulation |
| Immunofluorescence | Subcellular localization | ER membrane association and topology |
| CRISPR knockout | Loss-of-function phenotypes | Functional validation of squalene synthase in sterol synthesis |
| CRISPR knock-in | Point mutations or tags | Structure-function analysis of catalytic domains |
| RNA-seq | Transcriptome-wide changes | Pathway analysis upon squalene synthase perturbation |
Enzymatic assays for squalene synthase activity
Squalene synthase activity can be measured using radiometric assays that monitor the conversion of radiolabeled farnesyl diphosphate to squalene. Alternatively, spectrophotometric assays can follow NAD(P)H oxidation at 340 nm. These methods are essential for characterizing wild-type and mutant enzymes and for screening inhibitors.
Gene expression analysis
Quantitative RT-PCR and RNA-seq are used to measure FDFT1 mRNA levels under different conditions, such as sterol depletion or cytokine treatment. Western blotting and proteomics can quantify protein levels and post-translational modifications. These approaches help elucidate transcriptional and post-transcriptional regulation.
Subcellular localization studies
Immunofluorescence microscopy and subcellular fractionation are used to determine the localization of squalene synthase to the endoplasmic reticulum. Tagged versions of the enzyme (e.g., GFP-FDFT1) allow live-cell imaging and colocalization with ER markers. These studies reveal the membrane topology and trafficking of the enzyme.
CRISPR-based functional genomics
CRISPR knockout screens can identify genes that modulate squalene synthase activity or sterol biosynthesis. Point mutation knock-in via homology-directed repair enables structure-function analysis of catalytic residues. Overexpression models help assess the consequences of increased enzyme levels on lipid metabolism.
How CRISPR Can Be Used to Study GO:0051996 squalene synthase [NAD(P)H] activity
Knockout
CRISPR-Cas9 knockout of FDFT1 (squalene synthase) can be used to create cell lines completely lacking enzyme activity, allowing researchers to study the consequences of sterol pathway blockade. Such knockouts are typically lethal in organisms but viable in cultured cells supplemented with exogenous cholesterol or mevalonate. These models are valuable for dissecting the contribution of squalene synthase to cholesterol synthesis and cell proliferation.
Point Mutation
CRISPR-mediated point mutation knock-in can introduce specific amino acid substitutions in FDFT1 to test the roles of catalytic residues identified by structural studies. For example, mutations in the three catalytic domains can abolish or reduce enzyme activity, providing insights into the mechanism. These models are essential for validating structure-function predictions and for studying drug resistance mutations.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA, GFP) into the endogenous FDFT1 locus enables visualization and immunoprecipitation of squalene synthase at physiological expression levels. Tagged knock-in models are useful for studying subcellular localization, protein interactions, and turnover. They also facilitate chromatin immunoprecipitation and proteomic analyses.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase squalene synthase levels to study the effects of enzyme abundance on lipid metabolism and sterol synthesis. Overexpression models are particularly useful for assessing whether increased flux through the mevalonate pathway promotes cell growth or drug resistance. They can also be used to produce squalene or sterols in biotechnological applications.
How EDITGENE Supports squalene synthase [NAD(P)H] activity Research
Researchers studying squalene synthase [NAD(P)H] activity-related genes often need to determine whether a candidate gene is causally involved in sterol biosynthesis, metabolic regulation, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for squalene synthase [NAD(P)H] activity research.
Frequently Asked Questions About squalene synthase [NAD(P)H] activity
What is squalene synthase [NAD(P)H] activity?
Squalene synthase [NAD(P)H] activity (GO:0051996) is the enzyme activity that catalyzes the reductive dimerization of two farnesyl diphosphate molecules to form squalene, using NAD(P)H as a cofactor.
What genes are involved in squalene synthase [NAD(P)H] activity?
The primary gene is FDFT1, which encodes squalene synthase. Other genes in the pathway include HMGCR, FDPS, SQLE, and LSS.
What is the reaction catalyzed by squalene synthase?
The reaction is: 2 (2E,6E)-farnesyl diphosphate + H+ + NAD(P)H = 2 diphosphate + NAD(P)+ + squalene.
Where is squalene synthase located in the cell?
Squalene synthase is anchored to the endoplasmic reticulum membrane, with its catalytic domain facing the cytosol.
How is squalene synthase activity regulated?
It is regulated transcriptionally by SREBPs, post-transcriptionally by sterol feedback, and by inflammatory cytokines such as TNF and IL-1.
What diseases are associated with squalene synthase?
Squalene synthase is linked to hypercholesterolemia, cardiovascular disease, cancer metabolism, and infectious diseases caused by fungi and parasites.
What are the synonyms for squalene synthase [NAD(P)H] activity?
Synonyms include farnesyl-diphosphate farnesyltransferase activity, presqualene synthase activity, squalene synthase activity, and squalene synthetase activity.
How can I study squalene synthase activity in the lab?
Common methods include radiometric enzyme assays, spectrophotometric NAD(P)H oxidation assays, qRT-PCR, Western blotting, and CRISPR-based knockout or knock-in models.
Is squalene synthase a drug target?
Yes, it is a target for hypocholesterolemic drugs, antifungal agents, and antiparasitic compounds.
What is the role of NAD(P)H in the squalene synthase reaction?
NAD(P)H serves as the electron donor for the reductive step that converts presqualene diphosphate to squalene.
Conclusion
Squalene synthase [NAD(P)H] activity (GO:0051996) is a central molecular function in sterol biosynthesis, catalyzing the committed step that directs carbon flux toward cholesterol and related triterpenoids. Its unique two-step mechanism, membrane association, and complex regulation make it a fascinating subject for biochemical, structural, and pharmacological studies. Dysregulation of this activity is implicated in hypercholesterolemia, cancer, and infectious diseases, underscoring its therapeutic potential. Advanced CRISPR models and functional genomics tools now enable precise interrogation of squalene synthase biology, paving the way for new discoveries and drug development.
References
- 1. Tansey TR et al.. 2001. Squalene synthase: structure and regulation.. Prog Nucleic Acid Res Mol Biol 65:157-95 PMID: 11008488
- 2. Popják G et al.. 1979. Squalene synthetase.. Mol Cell Biochem 27(2):97-116 PMID: 41173
- 3. Tansey TR et al.. 2000. Structure and regulation of mammalian squalene synthase.. Biochim Biophys Acta 1529(1-3):49-62 PMID: 11111077
- 4. Okada S et al.. 2004. Characterization of botryococcene synthase enzyme activity, a squalene synthase-like activity from the green microalga Botryococcus braunii, Race B.. Arch Biochem Biophys 422(1):110-8 PMID: 14725863
- 5. Memon RA et al.. 1997. Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters.. J Lipid Res 38(8):1620-9 PMID: 9300784
- 6. Krisans SK et al.. 1994. Farnesyl-diphosphate synthase is localized in peroxisomes.. J Biol Chem 269(19):14165-9 PMID: 8188698
- 7. Stamellos KD et al.. 1993. Subcellular localization of squalene synthase in rat hepatic cells. Biochemical and immunochemical evidence.. J Biol Chem 268(17):12825-36 PMID: 8509416
- 8. Gu P et al.. 1998. Function-structure studies and identification of three enzyme domains involved in the catalytic activity in rat hepatic squalene synthase.. J Biol Chem 273(20):12515-25 PMID: 9575210
